Oncol Lett 17: [Related article:] 3817-3825, 2019; DOI:
10.3892/ol.2019.10017
Subsequently to the publication of this article, the
Editor of Oncology Letters received notification that the
use of the abbreviation “ISET” in this paper represented an
infringement of a trademark owned by the company “Rarecells”, who
are the exclusive licensee of several patents covering the “ISET”
system and of the ISET® device. Upon drawing this matter
to the authors' attention, they noted that their use of the term
“ISET” as an abbreviation was solely to represent the technique of
“isolation by size of epithelial tumor cells”. Nevertheless, so as
not to cause any confusion, the authors have agreed to the removal
of this abbreviation from their paper. Therefore, the term “ISET”
should not have been used in the following nine instances in this
article: p. 3817, the Abstract, lines 11 and 19; the Introduction,
lines 26 and 31; p. 3818, the subheading “ISET assay”; and
p. 3822, the Discussion, lines 10 and 11, and p. 3824, the second
paragraph, lines 6 and 8. Note that the online version of the paper
has been amended to reflect these changes.
The authors regret any inconvenience caused in this
regard. Note that these changes regarding the removal of the
abbreviation “ISET” from this article do not affect any of the
results or conclusions reported in this study.
